A series of 3,4,5-trisubstituted isothiazoles has been screened against HIV-1 (IIIB) and HIV-2 (ROD) at sub-toxic concentrations in acutely infected MT-4 cells. Among the tested compounds, only 3-mercapto-5-phenyl-4-isothiazolecarbonitrile was found to inhibit the replication of HIV-1 (IIIB) and HIV-2 (ROD) at 50% effective concentrations (EC50) of 7.8 and 9.7 μg/ml, respectively. The presence of a thioalkyl chain or dialkylamino function in the 3-position caused a loss of anti-HIV activity. New 4-cyano-5-phenylisothiazoles with other substituents in the 3-position have also been synthesized and studied as potential anti-HIV agents. Our results have demonstrated that 5-phenyl-3-(4-cyano-5-phenylisothiazol-3-yl) disulphanyl-4-isothiazolecarbonitrile and S-(4-cyano-5-phenylisothiazol-3-yl)-O-ethyl thiocarbonate are effective against both HIV-1 (IIIB) (EC50=13.6 and 15.2 μg/ml, respectively) and HIV-2 (ROD) (EC50=17.4 and 13.4 μg/ml, respectively).
ArtsEJ & WainbergMA (1996) Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrobial Agents & Chemotherapy40: 527–540.
2.
BabaMPauwelsRHerdewijnPDe ClercqEDesmyterJ & VandeputteM (1987) Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochemical & Biophysical Research Communications142: 128–134.
3.
Barré-SinoussiFChermannJCNugeyreMTChamaretSGruestJDauguetCAxler-BlinCVézinet-BrunFRouziouxCRozenbaumW & MontagnierL (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for AIDS. Science220: 868–871.
4.
CoatesJACammackNJenkinsonHJJowettAJJowettMIPearsonBAPennCRRousePLVinerKC & CameronJM (1992) 2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrobial Agents & Chemotherapy36: 733–739.
5.
CroweS (1999) New reverse transcriptase inhibitors. Advances in Experimental Medicine & Biology458: 183–197.
6.
CutrìCCCGarozzoASiracusaMASarvàMCTemperaGGeremiaEPinizzottoMR & GuerreraF (1998) Synthesis and antiviral activity of a new series of 4-isothiazolecarbonitriles. Bioorganic & Medicinal Chemistry6: 2271–2280.
7.
CutrìCCCGarozzoASiracusaMASarvàMCCastroAGeremiaEPinizzottoMR & GuerreraF (1999) Synthesis of new 3,4,5-trisubstituted isothiazoles as effective inhibitory agents of enteroviruses. Bioorganic & Medicinal Chemistry7: 225–230.
8.
CutrìCCCGarozzoASiracusaMACastroATemperaGSarvàMC & GuerreraF (2002) Synthesis of new 3-methylthio-5-aryl-4-isothiazolecarbonitriles with broad antiviral spectrum. Antiviral Research55: 357–368.
9.
DahlbergJEMitsuyaHBlamSBBroderS & AaronsonSA (1987) Broad spectrum antiretroviral activity of 2′,3′-dideoxynucleosides. Proceedings of the National Academy of Sciences, USA84: 2469–2473.
10.
DalugeSMGoodSSFalettoMBMillerWHStClairMHBooneLRTisdaleMParryNRReardonJEDornsifeREAverettDR & KrenitskyTA (1997) 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrobial Agents & Chemotherapy41: 1082–1093.
11.
De ClercqE (1997) In search of a selective antiviral chemotherapy. Clinical Microbiology Reviews10: 674–693.
HamamotoYNakashimaHMatsuiTMatsudaAUedaT & YamamotoN (1987) Inhibitory effect of 2′,3′-didehydro-2′,3′-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus. Antimicrobial Agents & Chemotherapy31: 907–910.
14.
HorwitzJPChuaJ & NoelM (1964) Nucleosides V, the monomesylates of 1-(2′-deoxy-β-D-lyxofuranosyl)thymine. Journal of Organic Chemistry29: 2076–2078.
15.
LinTSSchinaziRF & PrusoffWH (1987) Potent and selective in vitro activity of 3′-deoxythymidin-2′-ene (3′-deoxy-2′,3′-didehydrothymidine) against human immunodeficiency virus. Biochemical Pharmacology36: 2713–2718.
16.
MitsuyaHWeinholdKJFurmanPASt ClairMHLehrmanSNGalloRCBolognesiDBarryDW & BroderS (1985) 3′-Azido-3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/ lymphadenopathy-associated virus in vitro. Proceedings of the National Academy of Science, USA82: 7096–7100.
17.
MitsuyaH & BroderS (1986) Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proceedings of the National Academy of Sciences of Sciences, USA83: 1911–1915.
18.
MiyoshiITaguchiHKobonishiIYoshimotoSOhtsukiYShiraishiY & AkagiT (1982) Type C virus-producing cell lines derived from adult T cell leukemia. Gann Monography28: 219–228.
19.
NakagawaSOkumuraJSakaiFHoshiH & NaitoT (1970) Synthesis of sulfur-containing heterocycles using thionyl chloride or sulfur chlorides. Tetrahedron Letters42: 3719–3722.
PauwelsRDe ClercqEDesmyterJBalzariniJGoubauPHerdewijnPVanderhaegheH & VandeputteM (1987) Sensitive and rapid assay on MT-4 cells for the detection of antiviral compounds against the AIDS virus. Journal of Virological Methods16: 171–185.
22.
PauwelsRBalzariniJBabaMSnoeckRScholsDHerdewijnPDesmyterJ & De ClercqE (1988) Rapid and automated tetrazolium-based colorimetric assay for detection of anti-HIV compounds. Journal of Virological Methods20: 309–321.
23.
PopovicMSarngadharanMGReadE & GalloRC (1984) Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science224: 497–500.
24.
SchinaziRFChuCKPeckAMcMillanAMathisR & CannonD (1992) Activities of the four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrobial Agents & Chemotherapy36: 672–676.
25.
ValdezH (2002) Immune restoration after treatment of HIV-1 infection with highly active antiretroviral therapy (HAART). AIDS Review4: 157–164.
